|
1
|
Kivelä T: The epidemiological challenge of
the most frequent eye cancer: retinoblastoma, an issue of birth and
death. Br J Ophthalmol. 93:1129–1131. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chintagumpala M, Chevez-Barrios P, Paysse
EA, Plon SE and Hurwitz R: Retinoblastoma: review of current
management. Oncologist. 12:1237–1246. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chantada GL, Qaddoumi I, Canturk S, Khetan
V, Ma Z, Kimani K, Yeniad B, Sultan I, Sitorus RS, Tacyildiz N, et
al: Strategies to manage retinoblastoma in developing countries.
Pediatr Blood Cancer. 56:341–348. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Canturk S, Qaddoumi I, Khetan V, Ma Z,
Furmanchuk A, Antoneli CB, Sultan I, Kebudi R, Sharma T,
Rodriguez-Galindo C, et al: Survival of retinoblastoma in
less-developed countries impact of socioeconomic and health-related
indicators. Br J Ophthalmol. 94:1432–1436. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee YJ, Lee JH, Moon JH and Park SY:
Overcoming hypoxic resistance of tumor cells to TRAIL-induced
apoptosis through melatonin. Int J Mol Sci. 15:11941–11956. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gruber M and Simon MC: Hypoxia-inducible
factors, hypoxia, and tumor angiogenesis. Curr Opin Hematol.
13:169–174. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Greco S and Martelli F: MicroRNAs in
hypoxia response. Antioxid Redox Signal. 21:1164–1166. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McCarthy N: Hypoxia: micro changes. Nat
Rev Cancer. 14:382–383. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qin Q, Furong W and Baosheng L: Multiple
functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer
Res. 33:502014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu X, Jia R, Zhou Y, Song X, Wang J, Qian
G, Ge S and Fan X: Microarray-based analysis: Identification of
hypoxia-regulated microRNAs in retinoblastoma cells. Int J oncol.
38:1385–1393. 2011.PubMed/NCBI
|
|
12
|
Boutrid H, Jockovich ME, Murray TG, Piña
Y, Feuer WJ, Lampidis TJ and Cebulla CM: Targeting hypoxia, a novel
treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci.
49:2799–2805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lan KL, Lan KH, Sheu ML, Chen MY, Shih YS,
Hsu FC, Wang HM, Liu RS and Yen SH: Honokiol inhibits hypoxia-
inducible factor-1 pathway. Int J Radiat Biol. 87:579–590. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsai YP and Wu KJ: Hypoxia-regulated
target genes implicated in tumor metastasis. J Biomed Sci.
19:1022012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Voss MJ, Niggemann B, Zänker KS and
Entschladen F: Tumour reactions to hypoxia. Curr Mol Med.
10:381–386. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sudhakar J, Venkatesan N, Lakshmanan S,
Khetan V, Krishnakumar S and Biswas J: Hypoxic tumor
microenvironment in advanced retinoblastoma. Pediatr Blood Cancer.
60:1598–1601. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bao B, Ali S, Ahmad A, Azmi AS, Li Y,
Banerjee S, Kong D, Sethi S, Aboukameel A, Padhye SB, et al:
Hypoxia-induced aggressiveness of pancreatic cancer cells is due to
increased expression of VEGF, IL-6 and miR-21, which can be
attenuated by CDF treatment. PLoS One. 7:e501652012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kulshreshtha R, Ferracin M, Wojcik SE,
Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM,
Negrini M, et al: A microRNA signature of hypoxia. Mol Cell Biol.
27:1859–1867. 2007. View Article : Google Scholar :
|
|
19
|
He L, He X, Lim LP, De Stanchina E, Xuan
Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA
component of the p53 tumour suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sermeus A and Michiels C: Reciprocal
influence of the p53 and the hypoxic pathways. Cell Death Dis.
2:e1642011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kluiver J, van den Berg A, De Jong D,
Blokzijl T, Harms G, Bouwman E, Jacobs S, Poppema S and Kroesen BJ:
Regulation of pri-microRNA BIC transcription and processing in
Burkitt lymphoma. Oncogene. 26:3769–3776. 2007. View Article : Google Scholar
|
|
22
|
Koritzinsky M, Magagnin MG, van den
Beucken T, Seigneuric R, Savelkouls K, Dostie J, Pyronnet S,
Kaufman RJ, Weppler SA, Voncken JW, et al: Gene expression during
acute and prolonged hypoxia is regulated by distinct mechanisms of
translational control. EMBO J. 25:1114–1125. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao L and Ackerman SL: Endoplasmic
reticulum stress in health and disease. Curr Opin Cell Biol.
18:444–452. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xi Y, Formentini A, Chien M, Weir DB,
Russo JJ and Ju J, Kornmann M and Ju J: Prognostic values of
microRNAs in colorectal cancer. Biomark Insights. 2:113–121.
2006.
|
|
25
|
Nakajima G, Hayashi K, Xi Y, Kudo K,
Uchida K, Takasaki K, Yamamoto M and Ju J: Non-coding MicroRNAs
hsa-let-7g and hsa-miR-181b are associated with chemoresponse to
S-1 in colon cancer. Cancer Genomics Proteomics. 3:317–324.
2006.
|
|
26
|
Sun YC, Wang J, Guo CC, Sai K, Wang J,
Chen FR, Yang QY, Chen YS, Wang J, To TS, et al: miR-181b
sensitizes glioma cells to teniposide by targeting MDM2. BMC
Cancer. 14:6112014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takiuchi D, Eguchi H, Nagano H, Iwagami Y,
Tomimaru Y, Wada H, Kawamoto K, Kobayashi S, Marubashi S, Tanemura
M, et al: Involvement of microRNA-181b in the gemcitabine
resistance of pancreatic cancer cells. Pancreatology. 13:517–523.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He Y, Zhang H, Yu L, Gunel M, Boggon TJ,
Chen H and Min W: Stabilization of VEGFR2 signaling by cerebral
cavernous malformation 3 is critical for vascular development. Sci
Signal. 3:ra262010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu Y, Wu Q, Xu JF, Miller D, Sandalcioglu
IE, Zhang JM and Sure U: Differential angiogenesis function of CCM2
and CCM3 in cerebral cavernous malformations. Neurosurg Focus.
29:E12010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schleider E, Stahl S, Wüstehube J, Walter
U, Fischer A and Felbor U: Evidence for anti-angiogenic and
pro-survival functions of the cerebral cavernous malformation
protein 3. Neurogenetics. 12:83–86. 2011. View Article : Google Scholar :
|
|
31
|
You C, Sandalcioglu IE, Dammann P, Felbor
U, Sure U and Zhu Y: Loss of CCM3 impairs DLL4-Notch signalling:
implication in endothelial angiogenesis and in inherited cerebral
cavernous malformations. J Cell Mol Med. 17:407–418. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Perlman H, Suzuki E, Simonson M, Smith RC
and Walsh K: GATA-6 induces p21(Cip1) expression and G1 cell cycle
arrest. J Biol Chem. 273:13713–13718. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Crawford SE, Qi C, Misra P, Stellmach V,
Rao MS, Engel JD, Zhu Y and Reddy JK: Defects of the heart, eye,
and megakaryocytes in peroxisome proliferator activator
receptor-binding protein (PBP) null embryos implicate GATA family
of transcription factors. J Biol Chem. 277:3585–3592. 2002.
View Article : Google Scholar
|
|
34
|
Ji J, Yamashita T, Budhu A, Forgues M, Jia
HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, et al: Identification
of microRNA-181 by genome-wide screening as a critical player in
EpCAM-positive hepatic cancer stem cells. Hepatology. 50:472–480.
2009. View Article : Google Scholar : PubMed/NCBI
|
